Holen Sie sich die Stockscreener-App
53.77
0.89%
0.26
Schlusskurs vom Vortag:
$53.51
Offen:
$53.33
24-Stunden-Volumen:
28,410
Relative Volume:
0.16
Marktkapitalisierung:
$521.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.80M
KGV:
-22.01
EPS:
-2.4426
Netto-Cashflow:
$-14.56M
1W Leistung:
-11.47%
1M Leistung:
-32.09%
6M Leistung:
-27.15%
1J Leistung:
+3.12%
1-Tages-Spanne:
$53.00
$54.37
1-Wochen-Bereich:
$52.91
$62.45
52-Wochen-Spanne:
$48.94
$123.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Firmenname
Bright Minds Biosciences Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare DRUG vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
53.18 | 525.04M | 0 | -19.80M | -14.56M | -2.4426 |
VRTX
Vertex Pharmaceuticals Inc
|
521.13 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.95 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.22 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
960.17 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.81 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | Jefferies | Buy |
| 2025-09-08 | Eingeleitet | BTIG Research | Buy |
| 2025-05-13 | Eingeleitet | TD Cowen | Buy |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-01-23 | Eingeleitet | Piper Sandler | Overweight |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-01-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-26 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Bright Minds Biosciences Inc Aktie (DRUG) Neueste Nachrichten
Bright Minds Biosciences Inc. (DRUG) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Bright Minds Biosciences (NASDAQ:DRUG) Trading Down 6.9%Here's What Happened - MarketBeat
Bright Minds Biosciences Slides Under Pressure: Pre-Revenue Cash Burn and Insider Selling Weigh on Clinical-Stage Sentiment - kalkine.ca
Earnings Calendar for: - finance.yahoo.com
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Stock Rating Lowered by Zacks Research - MarketBeat
WHY Goldsky Resources (TSXV:GSKR), Dexterra Group (TSX:DXT), Bright Minds Biosciences (CN:DRUG), Magna Mining (TSX:NICU) and ADENTRA (TSX:ADEN) Could Put the TSX SmallCap Watchlist in Focus in September 2026 - kalkine.ca
Trading the Move, Not the Narrative: (DRUG) Edition - Stock Traders Daily
Top 10 Best Biotech Companies In Canada 2026 - Nubia Magazine!
Bright Minds Biosciences to Present at Upcoming Conferences - The Manila Times
Bright Minds Biosciences Stock Slides 4.82% as Biotech Volatility Bites: Is More Downside Pressure Ahead for CN:DRUG? - kalkine.ca
Bright Minds Biosciences Faces Fresh Pressure as Clinical Execution Risk Weighs on Sentiment - kalkine.ca
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Down 5.2%Time to Sell? - MarketBeat
Braidwell LP Decreases Stock Holdings in Bright Minds Biosciences Inc. $DRUG - MarketBeat
Bright Minds Biosciences Stock Falls 3.06%: CN:DRUG Faces Correction Pressure as Clinical and Valuation Risks Test Sentiment - kalkine.ca
Bright Minds Biosciences Inc (DRUG) Peer Comparison – Compare with Others - Value Research
Aptose Biosciences Inc. (APTO) Peer Comparison – Compare with Others - Value Research
DRUG: Bright Minds Biosciences Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Bright Minds Biosciences Inc (DRUG) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Bright Minds Biosciences Stock Falls 3.85%: Is CN:DRUG Facing Renewed Biotech Volatility as Clinical Risks Remain? - kalkine.ca
Bright Minds Biosciences Stock Faces Fresh Pressure as Biotech Sentiment Weakens - kalkine.ca
What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now? - Eastern Progress
13% Of This Bright Minds Biosciences Insider's Holdings Were Sold - simplywall.st
Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High? - finance.yahoo.com
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Wall Street Zen Upgrades Bright Minds Biosciences (NASDAQ:DRUG) to Hold - MarketBeat
Bright Minds Biosciences Stock Falls 4.60% as Investors Weigh BMB-101 Clinical Progress Against Biotech Development Risk - kalkine.ca
What is HC Wainwright's Forecast for DRUG FY2026 Earnings? - MarketBeat
Bright Minds Biosciences Slides as Biotech Volatility Returns — What Could Wake the Stock Up? - kalkine.ca
Bright Minds Biosciences Stock Faces Fresh Pressure — Can Clinical Momentum Offset Rising Correction Risk? - kalkine.ca
Psychedelic: Enveric, Helus, Bright Minds report earnings results - TipRanks
H.C. Wainwright reiterates Bright Minds stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Bright Minds stock rating at buy - Investing.com
Bright Minds Biosciences (NASDAQ:DRUG) Earns "Buy" Rating from HC Wainwright - MarketBeat
Bright Minds Biosciences Stock: An Epilepsy Story Keeps Drawing Biotech Money - kalkine.ca
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 5.9%Should You Buy? - MarketBeat
BTIG Research Reiterates "Buy" Rating for Bright Minds Biosciences (NASDAQ:DRUG) - MarketBeat
TD Cowen Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating - Moomoo
Bright Minds Biosciences (DRUG) Earnings Date and Reports 2026 $DRUG - MarketBeat
Liquidity Mapping Around (DRUG) Price Events - Stock Traders Daily
Bright Minds Biosciences (NASDAQ:DRUG) Issues Quarterly Earnings Results - MarketBeat
Bright Minds (DRUG) reports Phase 2 seizure gains in treatment‑resistant epilepsy - Stock Titan
Bright Minds Biosciences (DRUG): Cormorant Asset Management reports 9.17% ownership stake - Stock Titan
Bright Minds Biosciences (DRUG) Slips to $78.00 as Traders Eye Support at $74.1Chart Pattern Alerts - vinanet.vn
Can Bright Minds (TSX:DRUG) Keep Biotech Momentum Going? - Kalkine Media
Adage Capital (DRUG) discloses 3.41% Bright Minds Biosciences stake in latest holding - Stock Titan
Bright Minds Biosciences Inc. expected to post a loss of C$1.76 a shareEarnings Preview - TradingView
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet - finance.yahoo.com
Bright Minds Biosciences Inc (CN:DRUG) Shares Under Pressure as Biotech Sentiment Weakens and Development Risks Increase - kalkine.ca
Bright Minds: BMB-101 Takes Center Stage Ahead Of Phase 3 Pivotal Trials (NASDAQ:DRUG) - Seeking Alpha
Bright Minds Biosciences (CN:DRUG): The Ticker Everyone's Talking About After a US$175M Raise and a Seizure Data Bombshell - kalkine.ca
Finanzdaten der Bright Minds Biosciences Inc-Aktie (DRUG)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.00%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):